India has approved the “COVID-19 vaccine” from Bharat Biotech to be used for human trials, whereby making it to be the first candidate from the nation to acquire government’s green signal, while the number of cases continue to surge. India’s “Drug Controller General” has given the approval to the application of Bharat Biotics for conducting “a Phase I and II clinical trial of Covaxin”.
The said medicine was developed in association with the “Indian Council of Medical Research's National Institute of Virology”. In July, India will begin its human trial for the vaccine which has been manufactured in Hyderabad’s Genome Valley, wherein Bharat Biotech has its facility. According to aljazeera.com:
“India, which lags only the United States, Brazil and Russia in total cases, reported close to 20,000 new infections on Monday, according to data from the country's federal Ministry of Health.
“More than 16,000 people have died from the disease since the first case in India in January - low when compared with countries with similar numbers of cases”.
However, experts apprehend that the healthcare system may fail to cope with the situation given the country is density as the number of cases continue to rise. So far, no vaccine has received any commercial clearance, although more than a “dozen of vaccines”, contributed from over hundred candidates across the globe are in human trial stage.
References:
aljazeera.com
The said medicine was developed in association with the “Indian Council of Medical Research's National Institute of Virology”. In July, India will begin its human trial for the vaccine which has been manufactured in Hyderabad’s Genome Valley, wherein Bharat Biotech has its facility. According to aljazeera.com:
“India, which lags only the United States, Brazil and Russia in total cases, reported close to 20,000 new infections on Monday, according to data from the country's federal Ministry of Health.
“More than 16,000 people have died from the disease since the first case in India in January - low when compared with countries with similar numbers of cases”.
However, experts apprehend that the healthcare system may fail to cope with the situation given the country is density as the number of cases continue to rise. So far, no vaccine has received any commercial clearance, although more than a “dozen of vaccines”, contributed from over hundred candidates across the globe are in human trial stage.
References:
aljazeera.com